Kornimate/medical-research-clean huggingface dataset:
impact of compression garments on pain in patients with complex regional pain syndrome of the upper limbs.

Conditions: Complex Regional Pain Syndromes

Summary: the aim is to study another alternative for the treatment of pain in people with crps. indeed, the trab / medullary occupational therapy department of the cmrrf in kerpape used compression garments to reduce edema when it was present.in the case of crps of the upper limbs, gloves or compression sleeves are used to decrease the edema which is sometimes associated, although they are not supported for this indication. in this context, our clinical experience leads us to believe that there would also be some efficacy in neuropathic pain, this improvement being regularly described by patients.this study is expected to show a notable reduction in neuropathic pain thanks to the wearing of a compression garment.


Eligibility criteria:
inclusion criteria: * patients with crps of the upper limb with neuropathic pain * diagnosis of crps according to the budapest criteria * diagnosis of neuropathic pain according to dn4 * crps evolving for more than 3 months * no phlebitis or open sores on the upper limbs * patient consent to participate in the study * no modification of his drug treatment for 1 month * affiliation to a social security scheme or beneficiary of such a scheme exclusion criteria: * patient under guardianship, curatorship or safeguard of justice * psychiatric pathology altering the ability to consent * severe cognitive disorders that do not allow the patient to assess his pain * skin pathology preventing the wearing of the compression garment * patient who has previously worn a compression garment * history of vascular disorders of the upper limbs, lymph node dissection, or any other pathology that can lead to edema regardless of crps * known allergy to one of the components of the compression garments of the cerecare brand * declared pregnancy, breastfeeding woman or woman of childbearing potential without contraception * inability to put on the compression garment alone
preventing acute kidney injury and improving outcome in critically ill patients utilising risk prediction score

Conditions: Acute Kidney Injury; Critical Illness

Summary: an interventional controlled trial to test the feasibility of applying risk score based prevention for critically ill patient at high risk to develop acute kidney injury (aki)

background and rationale aki is common in the intensive care unit .it contributes significantly to mortality and morbidity .the estimated incidence or aki among critically ill patients is 30-40% and morality is high. there is a well recognized gap between the optimal care and the delivered care regarding prevention and management of aki. the focus over the last few years has been on early detection. a panel of urinary biomarkers have proved helpful for early detection of aki. however the cost and low specificity make no single one of them solely reliable .using a panel of bio-markers increases their specificity. the concept of electronic alerts has been recently introduced. some trials have been testing its impact on the outcome of aki. the benefit of electronic alerts is still uncertain .a meta-analysis is currently underway to synthesize stronger evidence of electronic alerts benefit. another evolving area, is the development of risk score to predict aki and and hence applying timely preventive measures. kdigo recommends applying preventive measures to high risk patients. however no study to date has tested risk scores based interventions hypothesis: we will use the recently validated score to predict aki in icu patients. we will then apply preventive measures. to patients at risk .to our knowledge this is the first study to apply preventive interventions based on aki risk score assessment

Eligibility criteria:
inclusion criteria: all adult patients (≥18 year old) admitted to the intensive care unit and do not fulfill the criteria for the diagnosis of aki by kidney disease improving global outcome (kdigo) definition exclusion criteria: 1. patients who have already developed aki at the time of intensive care unit icu admission. 2. patients with insufficient medical records to obtain previous medical history 3. patients who lack mental capacity

Keywords: risk score acute kidney injury critical care
innate immunity in allergic asthma

Conditions: Asthma

Summary: the purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. this type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.


Eligibility criteria:
inclusion criteria: * participants must be at least 18 years of age * no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma. exclusion criteria: * pregnant women and prisoners will be excluded from the study. * individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.

Keywords: allergy immunity healthy respiratory ent
stereotactic body radiotherapy or standard of care for prostate oligoprogressive cancer

Conditions: Castrate Resistance Prostate Cancer; OligoProgressive Metastatic Disease

Summary: this is a single centre, interventional, randomized phase ii, two-arm prospective trial investigating if stereotactic body radiotherapy (sbrt) to all sites of oligopressive (op) disease while remaining on current systemic therapy (st) will improve biochemical control compared to standard of care (soc) (which involves a change in st) for patients with op castrate resistance prostate cancer (crpc).

the current standard of care for patients with metastatic oligopressive (op) castrate resistance prostate cancer (crpc) is a change in systemic therapy (st). we propose that stereotactic body radiotherapy (sbrt) to oligopressive sites, while maintaining patients on their current systemic therapy, may allow for biochemical control of disease while maintaining patient quality of life and avoiding the toxicities associated with changing systemic therapy. we have proposed an initial prospective feasibility study, followed by a larger phase ii prospective study to investigate the efficacy of sbrt in oligopressive castrate resistance prostate cancer.

Eligibility criteria:
inclusion criteria: * age \>18 years * able to provide informed consent * histologic diagnosis of prostate adenocarcinoma * castrate resistance prostate cancer * radiographic evidence of \<10 sites of extra-cranial op metastatic lesions * receiving any line of st for \>3 months * all sites of op disease are amenable to and can be safely treated with sbrt * ecog performance status 0-3 exclusion criteria: * evidence of spinal cord compression * contraindication to radiotherapy

Keywords: systemic therapy stereotactic body radiation therapy (sbrt)
clinical study of ta-650 in patients with refractory kawasaki disease

Conditions: Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin

Summary: the purpose of this study is to evaluate the efficacy and safety of ta-650 in comparison with a control drug polyethylene glycol-treated human immunoglobulin (vgih) in patients with kawasaki disease refractory to initial therapy with intravenous immunoglobulin (ivig). the pharmacokinetics of ta-650 is also examined.


Eligibility criteria:
inclusion criteria: * patients diagnosed with kawasaki disease (incipient cases only) with 5 or more of the 6 major symptoms of kawasaki disease. * patients refractory to initial ivig therapy (a single administration at 2 g per kg body weight). * patients with a fever of 37.5ºc or higher axillary temperature at the time of enrollment. * patients to whom the study drug can be administered by day 8 of disease. exclusion criteria: * patients who have received vaccination with bacille calmette-guérin (bcg) vaccine within 6 months before the enrollment. * patients with a complication, or a history within 6 months before the enrollment of, serious infections requiring hospitalization. * patients with a complication, or a history within 6 months before the enrollment of, opportunistic infections. * patients complicated with active tuberculosis, active hepatitis b or c, or patients confirmed to be hepatitis b virus carriers or a history of hepatitis b. * patients confirmed to have hiv infection, or patients with a family history of hiv infection. * patients who have a history of receiving treatment with infliximab or other biological products. * patients who had participated in another clinical study and had received a study drug within 12 weeks before giving consent.

Keywords: infliximab remicade ta-650 intravenous immunoglobulin kawasaki disease ivig
tip bendable suction ureteral access sheath vs. traditional ureteral access sheath in retrograde intrarenal stone surgery

Conditions: Kidney Stone

Summary: nephrolithiasis is the most common chronic kidney condition and affecting approximately one in every 10-17 people in the world\[1,2\]. flexible ureteroscopy (f-urs) has become one of the most common treatments for ureteral and renal stones with minimal complications. the development of ureteral access sheath (uas) is a significant advance in flexible ureteroscopic management of urinary stones. the uas has two major advantages: 1) facilitating multiple entries into the renal collecting system without causing recurrent trauma to the ureter and permit expeditious basketing of multiple stone fragments, 2) improving the irrigation with better fluid outflow, thereby reducing the renal pelvic pressure (rpp) and risk of infectious complications. the tip bendable suction ureteral access sheath (s-uas) is a novel uas that has good flexibility and deformability at the tip, which can passively bend (bend \>90°) with the bending of f-urs and can connect to a vacuum suction device. preliminary study showed that s-uas can follow f-urs to cross the upj and into the renal pelvis and calices. s-uas close to the stone can achieve complete stone-free status in rirs. however, further clinical studies and comparisons with available techniques are required. this prospective, single-blinded, single-center, randomized control trial will evaluate the stone free rates, operative time, postoperative complications following rirs with s-uas. to the best of our knowledge, this is the first study to compare the clinical benefits of rirs with s-uas and traditional uas.


Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 years; * american society of anesthesiology score 1-3; * upper urinary stone (kidney stone or upper ureteral stone) diameter of ≤ 3 cm confirmed by ct; * capable of giving written informed consent, which includes adherence with the requirements of the trial. exclusion criteria: * patients with abnormal urinary tract anatomy (such as horseshoe kidney or ileal conduit); * patients with uncontrolled uti; * patients with health or other factors that are absolute contraindications to rirs; * patients unable to understand or complete trial documentation.

Keywords: kidney stone flexible ureteroscopy ureteral access sheath
efficacy of a rehabilitation program with the pediatric exoskeleton atlas 2030 in pediatric patients with cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is the first cause of motor disability in children worldwide. atlas 2030 is a robotic gait exoskeleton designed to rehabilitate children with motor disability. the objective of this study is to analyse the efficacy of a training program with atlas 2023 in chilren with cp.

a sample of children with cp will be divided into 2 groups, the experimental group will receive 32 sesions withe the atlas 2030 exoskeleton, whereas the control group will continue to receive their regular conventional therapy. assessments will be performed at the beginning and the end of the intervention, as well as after 6, 9 and 12 months of the end of the intervention for follow-up.

Eligibility criteria:
inclusion criteria: * medical authorization for standing, gait training and weight bearing. * informed consent signed by legal guardians. * confirmed diagnosis of cerebral palsy gmfcs levels iii or iv. * proper family acceptance and commitment level. * receiving a minimum of 2 hours of therapy/activities promoting physical activity. * maximum user weight of 35 kg. * hip width (between greater trochanteres) less than or equal to 35 cm. * length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 24cm to 33cm. * tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23cm to 32cm. * shoe size 27-33 (eu) exclusion criteria: * more than 8 sessions of robotic therapy during a month in the previous year to the beginning of the study. * intensive rehabilitation during the study. * imposibility of the family to fulfill treatment calendar. * spasticity equal to 4 on the modified ashworth scale at the time of use of the device. * more than 20º of hip and/or knee flessum at the time of using the exoskeleton. * necessity to walk with 10º of hip abduction. * necessity to walk with more than 9º of ankle dorsiflexion or plantar flexion or impossibility to use an orthosis to reach 90º in the ankle joint. * severe skin lesion on parts of the lower extremities that are in contact with the device. * scheduled surgery (rachis, limbs) for the duration of the study or surgery performed (rachis, extremities) in the last 6 months. * history of fracture without trauma. history of bone fracture traumatic in lower extremities or pelvic girdle in the last 3 months. * severe rigid orthopedic deformities of the spine and/or lower limbs. * cognitive or conductual disorders that may lead to a lack of adherence to the attachment to the device. * conditions that provoke exercise intolerance. * conductual disorders that may interfere with the use of the device or their participation in the study, like impulsiveness or the inability to understand simple comands. * allergy to any of the atlas materials: cotton, nylon, polyester, polyamide, polyethylene or propylene.

Keywords: exoskeleton cerebral palsy gait rehabilitation
effect of postextubation high-flow nasal cannula vs noninvasive ventilation in patients with hypercapnic copd

Conditions: High-Flow Nasal Cannula; COPD

Summary: to test if high-flow conditioned oxygen therapy is noninferior to niv for preventing postextubation respiratory failure and reintubation in patients with hypercapnic copd, investigators plan to conduct the participants level, 1:1 randomized trial at the respiratory icu. participants were randomized to undergo either high-flow conditioned oxygen therapy or noninvasive mechanical ventilation after extubation. primary outcomes were reintubation and postextubation respiratory failure within 72 hours. secondary outcomes included length of ricu stay after extubation and mortality; partial pressure of arterial carbon dioxide.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of aecopd * extubation must be performed after 48 hours of invasive ventilation * must be treated sequentially with hfnc or niv after extubation * paco2≥50mmhg when extubation * positive end expiratory pressure (peep) ≤8cmh2o (1cmh2o=0.098 kpa) when extubation exclusion criteria: * do-not-intubate * tracheostomies * accidental extubation * self-extubation
escalating dose study in subjects with relapsed or refractory b cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and waldenstrom's macroglobulinemia

Conditions: B Cell Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia

Summary: the purpose of this study is to evaluate the safety and tolerability of avl-292 as monotherapy in subjects with relapsed or refractory b cell non-hodgkin lymphoma (b-nhl), chronic lymphocytic leukemia (cll) or waldenstrom's macroglobulinemia (wm).

bruton's tyrosine kinase (btk) is non-receptor tyrosine kinase with restricted cellular expression largely limited to b-lymphocytes, monocytes, and mast cells or basophils. btk is a critical component of the b cell receptor (bcr) signaling network and is crucial for b cell development. investigation has revealed that some b cell lymphomas and cll depend on bcr signaling, suggesting that interruption of such signaling could be a promising therapeutic opportunity in b-nhl, cll and wm.

Eligibility criteria:
inclusion criteria: * women and men ≥18 years of age * body weight ≥50 kg. * confirmed diagnosis of b cellnon-hodgkin lymphoma(according to world health organization \[who\] classification)including chronic lymphocytic leukemia/small cell lymphocytic leukemia (international workshop),or waldenstrom's macroglobulinemia(second international workshop) * have failed ≥1 previous treatment for b-nhl/cll/wm, and have relapsed or refractory disease following last prior treatment. * eastern cooperative oncology group performance status of ≤ 2 and a life expectancy of at least 3 months. * ability to swallow oral capsules without difficulty * has recovered from adverse toxic effects of prior therapies * meet the following clinical laboratory requirements: * creatinine ≤ 1.5 × upper limit of normal (uln) * total bilirubin ≤ 1.5 x uln * ast and alt ≤ 3 × uln * platelet count ≥ 50,000/µl (non-hodgkin \& waldenstrom's) * platelet count ≥ 30,000/µl (chronic lymphocytic leukemia) * absolute neutrophil count ≥ 1000/µl exclusion criteria: * prior allogeneic bone marrow transplant * autologous stem cell transplant within 3 months of screening * active central nervous system involvement * subjects with autoimmune hemolytic anemia or immune thrombocytopenia * prior treatment with a btk inhibitor * active uncontrolled infection * history of malabsorption * uncontrolled illness, i.e cardiac, endocrine, respiratory, etc. * history of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or stenting with in the previous 6 months * history of another currently active cancer * history of major surgery within 4 weeks or minor surgery within 1 week * other medical or psychiatric illness or organ dysfunction * hiv positive * positive for hepatitis b surface antigen or hepatitis c-virus

Keywords: non-hodgkin's lymphoma lymphoma leukemia chronic lymphocytic leukemia b-cell malignancies btk inhibitor phase 1b avila therapeutics waldenstrom macroglobulinemia
impact of lactoferrin, a dietary supplement, vs. placebo on respiratory tract infections

Conditions: Immune Health

Summary: this is a randomized, double-blind, placebo-controlled study to evaluate the impact of bovine lactoferrin (blf) on respiratory tract infections (rtis) in an elderly population in the united states.


Eligibility criteria:
inclusion criteria: * aged ≥ 55 years of age at time of consent * able to eat and drink, with assistance if required * investigator and community living center administration expect subject to reside in community living center for the duration of the study * signed consent obtained from subject or legally authorized representative * signed authorization obtained to use and/or disclose protected health information exclusion criteria: * receiving (or, in the opinion of the investigator, likely to receive in the next 6 months) parenteral nutrition * have a known eating disorder or illness, which requires a therapeutic diet incompatible with fortification and/or supplementation * has been diagnosed as immunocompromised or is receiving medication which may cause immune compromise. note relative immunocompromisation due to age would not exclude the subject * known allergy or intolerance to study products * on an end-of-life care pathway or, in the opinion of the investigator, has a life expectancy of less than 6 months * inappropriate for inclusion in the study in the opinion of the investigator or community living center administration * have experienced respiratory tract infection within 1 week prior to randomization
the cardiac effects of empagliflozin in patients with high risk of heart failure

Conditions: Heart Failure; Obesity

Summary: the aim of this trial is to assess the effect of empagliflozin on cardiac mass, volumes, cardiac biomarkers, metabolism, daily activity level, health-related quality of life in patients in elderly and obese patients with increased risk of developing heart failure. the primary hypotheses are that 180 days of treatment with empagliflozin 10 mg a day will: 1) reduce left ventricular mass index, and 2) increase peak vo2 (maximal oxygen consumption) compared with placebo.

the empire prevent: cardiac is a part of the empire prevent trial program, which also comprises the empire prevent: metabolic

Eligibility criteria:
inclusion criteria: * body mass index \>28kg/m2 * age 60-84 years * established risk factor for developing heart failure, defined as at least one of the following: * hypertension * ischemic heart disease * stroke/transient cerebral ischemia * chronic kidney disease (egfr 30-45ml/min/1.73m2) exclusion criteria: * diabetes mellitus type 1 or 2 (no medical history, no antidiabetic treatment) * heart failure with reduced ejection fraction (lvef \<40%) * inability to perform exercise test * dementia * severe non-compliance * substance abuse * severe chronic obstructive pulmonary disease (fev1\<50% expected value) * permanent atrial fibrillation * gfr \<30 ml/min/1,73m2 * severe peripheral artery disease * cancer treatment within one year beside prostate cancer and basal cell carcinoma * severe aortic or mitral valve disease * pregnancy or breastfeeding * acute hospital admission within 30 days * participation in other pharmacological study